Lexaria Bioscience (LEXX) Institutional Ownership $0.92 +0.03 (+2.91%) As of 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Lexaria Bioscience (NASDAQ:LEXX)CurrentInstitutional OwnershipPercentage13.06%Number ofInstitutional Buyers(last 12 months)9TotalInstitutional Inflows(last 12 months)$3.68MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$251.88K Get LEXX Insider Trade Alerts Want to know when executives and insiders are buying or selling Lexaria Bioscience stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data LEXX Institutional Buying and Selling by Quarter Lexaria Bioscience Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/16/2025Invenomic Capital Management LP549,947$940K0.0%+33.9%3.132% 4/16/2025 Byrne Asset Management LLC28,905$49K0.0%+122.3%0.165% 3/17/2025 Wealth Enhancement Advisory Services LLC28,873$61K0.0%+108.9%0.164% 2/17/2025Invenomic Capital Management LP410,731$863K0.0%-13.7%2.340% 2/13/2025Raymond James Financial Inc.60,640$127K0.0%N/A0.346% 2/12/2025Geode Capital Management LLC166,679$350K0.0%+10.8%0.950% 2/7/2025HighTower Advisors LLC21,023$44K0.0%+61.4%0.120% 2/6/2025Raymond James Financial Inc.60,640$127K0.0%N/A0.346% 1/28/2025 Byrne Asset Management LLC13,000$27K0.0%+132.1%0.074% 11/16/2024Geode Capital Management LLC150,391$459K0.0%+31.0%0.951% Get the Latest News and Ratings for LEXX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter. 11/15/2024XTX Topco Ltd18,626$57K0.0%+47.8%0.118% 11/15/2024Invenomic Capital Management LP475,773$1.45M0.1%-7.4%3.007% 11/15/2024HighTower Advisors LLC13,023$40K0.0%N/A0.082% 8/15/2024Armistice Capital LLC1,020,000$2.84M0.0%N/A7.916% 8/9/2024Renaissance Technologies LLC22,800$63K0.0%N/A0.177% 5/16/2024Invenomic Capital Management LP473,265$1.72M0.1%-35.3%3.672% 4/9/2024 Welch Group LLC24,000$87K0.0%N/A0.194% 2/14/2024Invenomic Capital Management LP731,981$915K0.0%-4.2%7.011% 2/8/2024Cowen AND Company LLC256,327$320K0.1%N/A2.455% 11/15/2023Armistice Capital LLC889,272$889K0.0%N/A10.992% 8/14/2023Invenomic Capital Management LP766,573$560K0.0%+62.0%9.476% 8/8/2022 Merit Financial Group LLC21,267$63K0.0%N/A0.357% 2/11/2022Invenomic Capital Management LP359,113$1.45M0.3%+1.9%6.034% 11/15/2021MD Financial Management Inc.407,687$2.55M0.1%+15,078.2%7.988% 8/16/2021Invenomic Capital Management LP317,110$2.22M0.5%+7.1%6.213% 8/13/2021Renaissance Technologies LLC17,200$120K0.0%N/A0.337% 8/13/2021Geode Capital Management LLC50,385$352K0.0%N/A0.987% 8/13/2021Vanguard Group Inc.25,976$182K0.0%N/A0.509% 5/21/2021Citadel Advisors LLC14,915$84K0.0%N/A0.292% 5/18/2021Citadel Advisors LLC14,915$84K0.0%N/A0.292% (Data available from 1/1/2016 forward) LEXX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LEXX shares? During the previous two years, 11 institutional investors and hedge funds held shares of Lexaria Bioscience. The most heavily invested institutionals were Armistice Capital LLC ($2.84M), Invenomic Capital Management LP ($940K), Geode Capital Management LLC ($350K), Cowen AND Company LLC ($320K), Raymond James Financial Inc. ($127K), Welch Group LLC ($87K), and Renaissance Technologies LLC ($63K).Learn more on Lexaria Bioscience's institutional investors. What percentage of Lexaria Bioscience's stock is owned by institutional investors? 13.06% of Lexaria Bioscience's stock is owned by institutional investors. Learn more on LEXX's institutional investor holdings. Which institutional investors have been buying Lexaria Bioscience's stock? Of the 11 institutional investors that purchased Lexaria Bioscience's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Armistice Capital LLC ($1.91M), Invenomic Capital Management LP ($432.69K), Cowen AND Company LLC ($256.33K), Raymond James Financial Inc. ($121.28K), Geode Capital Management LLC ($51.90K), Welch Group LLC ($24K), and Byrne Asset Management LLC ($23.31K). How much institutional buying is happening at Lexaria Bioscience? Institutional investors have bought a total of 1,420,594 shares in the last 24 months. This purchase volume represents approximately $3.68M in transactions. Which of Lexaria Bioscience's major shareholders have been selling company stock? The following institutional investors have sold Lexaria Bioscience stock in the last 24 months: Invenomic Capital Management LP ($102.84K). How much institutional selling is happening at Lexaria Bioscience? Institutional investors have sold a total of 102,842 shares in the last 24 months. This volume of shares sold represents approximately $251.88K in transactions. Related Companies OTLK Institutional Ownership SRZN Institutional Ownership CELU Institutional Ownership PYXS Institutional Ownership BMEA Institutional Ownership INCR Institutional Ownership PMVP Institutional Ownership GNTA Institutional Ownership QNTM Institutional Ownership TELO Institutional Ownership This page (NASDAQ:LEXX) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredStrange Investment Secret Predicts Market's Next Move?A strange market signal discovered before the Great Depression has predicted nearly every major financial even...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LEXX Stock Alerts